Pyxis Oncology, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 21, 2024; clinical and financing updates after year-end are identified below. Pyxis Oncology is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) and immuno-oncology therapies, primarily for solid tumors. It has no approved products and has generated no product-sales revenue.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $49.6 million | $86.1 million |
| General and administrative expense | $32.6 million | $37.4 million |
| Total operating expenses | $82.2 million | $123.5 million |
| Net loss | $73.8 million | $120.7 million |
| Net loss per share, basic and diluted | $1.85 | $3.65 |
| Net cash used in operating activities | $70.7 million | $89.3 million |
At December 31, 2023, cash and cash equivalents were $9.7 million and short-term U.S. Treasury securities were $109.6 million, for combined cash, cash equivalents and short-term investments of $119.3 million. Total liabilities were $48.0 million and stockholders’ equity was $125.7 million. The filing reports no borrowings; lease liabilities were $21.3 million, including current and long-term portions. Net lease payments after scheduled sublease receipts were $28.1 million undiscounted over the remaining lease term.
Interest and investment income was $6.6 million, including $4.8 million of discount accretion on Treasury securities; sublease income was $1.8 million. These items contributed to the year-over-year reduction in net loss. The filing reports no product revenue or meaningful operating margin to assess.
Operating cash use declined year over year. The $104.8 million of investing cash use in 2023 mainly reflected Treasury security purchases, partly offset by maturities; it should not be read as operating cash burn. Year-end cash-flow-statement cash, cash equivalents and restricted cash totaled $11.1 million, distinct from the $119.3 million liquidity figure that includes short-term investments.
Material changes and notable events
- Net loss narrowed by $46.9 million from 2022, alongside $41.3 million lower operating expenses. R&D expense fell by $36.5 million, primarily because of prior-year Pfizer and Biosion license payments, lower manufacturing costs and paused preclinical programs; clinical-trial spending for PYX-201 and PYX-106 increased.
- Pyxis acquired Apexigen in August 2023 for consideration valued at approximately $10.7 million, principally adding the CD40 agonist PYX-107 and the APXiMAB antibody-discovery platform. The acquisition added $24.5 million of intangible assets, including $21.0 million of in-process R&D; the purchase-price allocation was described as provisional.
- In November 2023, the company announced a reorganization and reduced headcount by approximately 40% to prioritize clinical development. The reorganization was completed in Q4.
- After year-end, the Voxall joint venture with Alloy Therapeutics was dissolved by mutual decision in February 2024. Alloy retained rights to certain intellectual property.
Pipeline, outlook and key risks
- PYX-201: Phase 1 dose-escalation study of an ADC targeting EDB+FN in tumor stroma. By the filing date, 37 subjects had been dosed; the company reported no significant target-mediated toxicities, grade 2 treatment-emergent adverse events in approximately 54% and grade 3 events in approximately 6%, with no reported event causing a dosing delay or discontinuation. These are early, company-reported safety observations, not evidence of established efficacy. The study advanced to an 8 mg/kg cohort in March 2024. The company anticipated reporting safety, efficacy and PK/PD data in fall 2024. PYX-201 received FDA Orphan Drug Designation for pancreatic cancer.
- PYX-106: First-in-human Phase 1 study of an anti-Siglec-15 antibody. By the filing date, 21 subjects had been dosed and Cohort 5 at 8 mg/kg was fully enrolled. Preliminary PK/PD and early activity data were anticipated in the second half of 2024.
- PYX-107: Acquired CD40 agonist with prior clinical-trial experience. In a cited Phase 2 melanoma study with nivolumab, the company reported a 15.2% partial response rate and 30.3% stable disease rate among efficacy-evaluable patients. The filing also describes serious adverse events in a separate esophageal/GEJ combination study, including cytokine release syndrome in three patients and Guillain-Barré syndrome in one. Pyxis said further development would be assessed as part of portfolio evaluation; historical results are not Pyxis-sponsored confirmatory evidence.
- Funding outlook: After year-end, the company received $10.8 million gross from ATM sales in January 2024 and completed a private placement for approximately $50 million gross in February 2024. Management estimated these proceeds plus year-end resources would fund operations into the second half of 2026. This is a forward-looking estimate based on assumptions; the company states that available capital may be used sooner and will not fund any candidate through regulatory approval.
- Principal risks: substantial ongoing losses and future financing needs; uncertain clinical and regulatory outcomes; reliance on third-party manufacturers and CROs, including some manufacturing in China and potential single-source materials; competition; and dependence on licensed intellectual property and agreements. Equity financing may dilute existing holders.
- Novartis royalty dispute: Novartis disputes its obligation to pay royalties on Beovu sales under an agreement assumed through Apexigen and continues paying under protest. Pyxis constrained the royalty proceeds and recorded $7.7 million as deferred revenue at year-end; recognition, future payments and retention of previously received amounts remain uncertain.
- Other commitments and controls: The company’s Boston lease runs through 2032, with a sublease through March 2026, while Pyxis remains responsible under the head lease. Management reported effective disclosure controls and internal control over financial reporting as of December 31, 2023; the auditor expressed an unqualified opinion on the financial statements but did not audit internal control effectiveness. No material legal proceedings were reported.
Most important facts for investors to verify
- Actual cash use, liquid resources and runway against the “second half of 2026” estimate, including the net proceeds and dilution from the 2024 ATM and private placement.
- Updated PYX-201 and PYX-106 trial enrollment, dose escalation, adverse events, PK/PD and efficacy results, and whether expected data disclosures occurred.
- Management’s decision and resourcing for PYX-107 following portfolio evaluation, and how its historical study results compare with subsequent evidence.
- Status and accounting treatment of the $7.7 million constrained Beovu royalty balance, including any resolution with Novartis and potential repayment exposure.
- Acquisition-related intangible asset valuation and impairment assumptions, as well as continuing lease costs and obligations.